Radium-223 Chloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Trial Profile

Radium-223 Chloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 14 Sep 2015

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Expanded access; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 14 Sep 2015 Overall survival results will be presented at the 2015 European Cancer Congress, according to a Bayer media release.
    • 02 Jun 2015 Results of pain assessment in 182 patients with baseline pain scores presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 23 Feb 2015 According to a Bayer HealthCare Pharmaceuticals media release, data from this study will be presented at the 2015 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top